Tetra Bio-Pharma Inc. is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain.
Tetra Bio-Pharma Inc. today announced that the company has provided an extension to North Bud Farms Inc. Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the final receipt of North Bud’s prospectus’.
Tetra Bio-Pharma Inc. today announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings, to discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa™ mucoadhesive product, PPP002.
Tetra Natural Health Inc. announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a Temporary Marketing Authorization (TMA) by Health Canada.
Tetra Bio-Pharma Inc. today announced a co-development agreement with Storz & Bickel to use a specialized medical device known as the Mighty Medic, in combination with its PPP001 prescription drug as well as with additional indications and a future proprietary cannabinoid formulation.
Tetra Bio-Pharma Inc. today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model.
Tetra Bio-Pharma Inc. is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.
Tetra Bio-Pharma Inc. is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial.
Tetra Bio-Pharma Inc. is pleased to provide a Corporate Update on its programs and upcoming milestones in the development of its bio-pharmaceutical and natural health products that address large markets with significant unmet medical needs.
Tetra Bio-Pharma Inc., a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. André Rancourt has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation